Cost-Benefit Analysis of Amtolmetin-Guacil

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.21, Iss.1, 2001-01, pp. : 47-58

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Amtolmetin guacil and celecoxib, easy on the stomach

Reactions Weekly, Vol. 1, Iss. 1089, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

A Meta-Analysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal Anti-Inflammatory Drug, Compared with Established Agents

By Marcolongo R. Frediani B. Biasi G. Minari C. Barreca C.

Clinical Drug Investigation, Vol. 17, Iss. 2, 1999-02 ,pp. : 89-96

Adis International

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A Veenstra David Bebber Stephanie Van Sakowski Julie

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

A cost–benefit analysis of chemotherapy for gastric cancer

By Galizia Eva Berardi Rossana Scartozzi Mario Cascinu Stefano

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2109-2114

Informa Healthcare

Access to resources Recommend Favorite

Cost-benefit or cost-utility analysis?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 315, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite